LB54640

DRUG2 trials

Sponsors

LG Chem, Rhythm Pharmaceuticals, Inc.

Conditions

Hypothalamic ObesityLEPR Deficiency ObesityPCSK1 Deficiency ObesityPOMC Deficiency Obesity

Phase 2

A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

LG ChemLEPR Deficiency Obesity, PCSK1 Deficiency Obesity, POMC Deficiency Obesity

Start: 2023-12-31End: 2025-12-31Target: 4Updated: 2023-11-02

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

CompletedNCT06046443

Rhythm Pharmaceuticals, Inc.Hypothalamic Obesity

Start: 2024-07-11End: 2026-02-09Updated: 2026-02-12